Tuesday November 24 2009 | Biotechnology feed | All feeds
|
|
Tuesday November 24 2009 | Biotechnology feed | All feeds
|
|
|
Human leukocyte
elastase (HLE) is a proteinase capable of degrading a variety of proteins.
Under normal circumstances, natural inhibitors control the proteolytic
activity of HLE. However, an imbalance between elastase and these endogenous
inhibitors may result in several pathophysiological states such as chronic
obstructive pulmonary disease, asthma, emphysema, cystic fibrosis and chronic
inflammatory diseases. It is anticipated that an orally active HLE inhibitor
could be useful for the treatment of these diseases. Despite the
therapeutic implications of elastase inhibitors the drug development community
has so far failed to make major advances in the development of this
therapeutic class. Aventis have developeda formulation of alpha-1 protease
inhibitor, an endogenous protease inhibitor. Dyax are developing a similar
molecule. With regards to small molecule inhibitors, most advanced is Ono’s
Sivelestat (ONO-5046) which is a neutrophil elastase inhibitor, launched in
2002 for the treatment of acute lung injury caused by systemic inflammatory
response syndrome (SIRS). This molecule is in earlier stage development for
idiopathic pulmonary fibrosis (IPF) and chronic airway infection. Both Roche
and Dainippon have also recently advanced inhibitors into phase I trials for
the treatment of lung conditions. One of the most
recent elastase inhibitors to have been reported is Sanofi-Synthelabo’s
SSR69071. We introduced this molecule in the previous edition of
TherapeuticAdvances describing its efficacy in a model of coronary
ischemia and reperfusion. SSR69071 is nanomolar inhibitor of human, rat, mouse
and rabbit elastases. Oral treatment of mice with SSR69071 inhibits HLE
activity measured in recovered bronchoalveolar lavage fluid from mice, and
potently decreases acute lung hemorrhage induced by HLE (ED50=2.8 mg/kg po).
Furthermore, SSR69071 prevents carrageenan and HLE-induced paw edema in rats
after oral administration. In addition to previously reported cardiovascular efficacy, SSR69071 may also represent an excellent candidate for the treatment of inflammatory disease in particular, because of its good penetration in respiratory tissues, diseases characterized by airway inflammation. Entry date Adapted from Kapui et al, J Pharmacol Exp Ther 2003 Feb 11; [epub ahead of print]
Interested in collaborating with this group? Contact leaddiscovery@bioportfolio.co.uk Projects such as these are overviewed in full DiscoveryDossiers. LeadDiscovery and BioPortfolio aims to provide reliable, insightful analysis on the biotechnology industry. However, this information is provided "as is" and no representations or warranties either express or implied of completeness, accuracy, or of any other nature are made with respect to this information. This information is neither an offer to sell nor a solicitation to buy the securities of any company. This information contains forward-looking statements, which involve risks and uncertainties which may not be listed. The biotechnology industry is an emerging industry and the securities of the companies mentioned in this report have a very high degree of risk and volatility. For this reason, this information is supplied on the condition that the reader will make his or her own determination as to its suitability for any purpose prior to any use of this information. The employees and officers of LeadDiscovery and BioPortfolio may hold positions in some or all of the stocks discussed in this report. This abstract has been produced by LeadDiscovery Ltd. Founded by life scientists for life scientists we aim to help industry identify cutting edge drug discovery options and academic/biotech institutions maximize the potential of their research. Abstracts strictly reflect the opinion of LeadDiscovery's editorial panel. While all reasonable efforts are made to ensure the accuracy of information provided LeadDiscovery and the publisher BioPortfolio, takes no responsibility for incorrect or misleading information. LeadDiscovery is designed for educational and drug development purposes only and is not intended or designed to offer medical advice or advice of any sort, and must not be used for such purpose. The information provided through LeadDiscovery and BioPortfolio should not be used for diagnosing or treating a health problem or a disease and no reliance should be placed on any information contained in this abstract or elsewhere on LeadDiscovery's and BioPortfolio's website. It is not intended to be a substitute for professional care. If you have or suspect you may have a health problem, you should consult your physician or other health care provider. |
|
|
